Transthyretin accelerates vascular Aβ deposition in a mouse model of Alzheimer's disease

Brain Pathology

Volumn 19, Issue 1, 2009, Pages 48-57

  Wati, Henny ^a   Kawarabayashi, Takeshi ^b   Matsubara, Etsuro ^c   Kasai, Ayumi ^a   Hirasawa, Takae ^a   Kubota, Takeo ^a   Harigaya, Yasuo ^d   Shoji, Mikio ^b   Maeda, Shuichiro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^d MAEBASHI RED CROSS HOSPITAL   (Japan)

Author keywords

Alzheimer's disease; Amyloid ; Apoptosis; Tau phosphorylation; Tg2576 mouse; Transthyretin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; COMPLEMENTARY DNA; PREALBUMIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; GENE; GENE LOCUS; HIPPOCAMPUS; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PROTEIN PHOSPHORYLATION; TTR GENE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BLOOD VESSELS; BLOTTING, WESTERN; BRAIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HETEROZYGOTE; HIPPOCAMPUS; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PREALBUMIN; SENILE PLAQUES;

EID: 57449087930     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2008.00166.x     Document Type: Article

References (55)

1. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM (1998) Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol 57 : 353 359.
2. Biroccio A, Del Boccio P, Panella M, Bernardini S, Di Ilio C, Gambi D et al (2006) Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 6 : 2305 2313.
3. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA et al (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 : 939 945.
4. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A et al (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3 : 855 859.
5. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82 : 239 259.
6. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8 : 1390 1397.
7. Castano EM, Prelli F, Soto C, Beavis R, Matsubara E, Shoji M, Frangione B (1996) The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J Biol Chem 271 : 32185 32191.
8. Choi SH, Leight SN, Lee VM, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS (2007) Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 27 : 7006 7010.
9. Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ (1993) Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA 90 : 2375 2379.
10. Giunta S, Valli MB, Galeazzi R, Fattoretti P, Corder EH, Galeazzi L (2005) Transthyretin inhibition of amyloid beta aggregation and toxicity. Clin Biochem 38 : 1112 1119.
11. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 : 353 356.
12. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ et al (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97 : 2892 2897.
13. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S et al (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 : 99 102.
14. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W et al (1995) Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15 : 1203 1218.
15. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997) APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56 : 965 973.
16. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17 : 157 165.
17. Joachim CL, Duffy LK, Morris JH, Selkoe DJ (1988) Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer's disease and normal aging. Brain Res 474 : 100 111.
18. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21 : 372 381.
19. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA (1995) Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1 : 143 148.
20. Lazarov O, Lee M, Peterson DA, Sisodia SS (2002) Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22 : 9785 9793.
21. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM et al (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120 : 701 713.
22. Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92 : 9368 9372.
23. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372 : 92 94.
24. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D et al (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 85 : 1101 1108.
25. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y et al (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45 : 537 541.
26. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V et al (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23 : 29 33.
27. Noda-Saita K, Terai K, Iwai A, Tsukamoto M, Shitaka Y, Kawabata S et al (2004) Exclusive association and simultaneous appearance of congophilic plaques and AT8-positive dystrophic neurites in Tg2576 mice suggest a mechanism of senile plaque formation and progression of neuritic dystrophy in Alzheimer's disease. Acta Neuropathol (Berl) 108 : 435 442.
28. Nunes AF, Saraiva MJ, Sousa MM (2006) Transthyretin knockouts are a new mouse model for increased neuropeptide Y. Faseb J 20 : 166 168.
29. Prelli F, Castano E, Glenner GG, Frangione B (1988) Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 51 : 648 651.
30. Qiu WQ, Folstein MF (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 27 : 190 198.
31. Rensink AA, de Waal RM, Kremer B, Verbeek MM (2003) Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 43 : 207 223.
32. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T (2006) Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci USA 103 : 18787 18792.
33. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R et al (2007) Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med 13 : 1029 1031.
34. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, a beta N3(pE), in senile plaques. Neuron 14 : 457 466.
35. Sasaki A, Shoji M, Harigaya Y, Kawarabayashi T, Ikeda M, Naito M et al (2002) Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites. Virchows Arch 441 : 358 367.
36. Schwarzman AL, Goldgaber D (1996) Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Ciba Found Symp 199 : 146 160. discussion AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ et al (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 91 : 8368 8372.
37. Serot JM, Christmann D, Dubost T, Couturier M (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 63 : 506 508.
38. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D et al (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 : 325 327.
39. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM et al (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258 : 126 129.
40. Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA (2007) Transthyretin and Alzheimer's disease: where in the brain? Neurobiol Aging 28 : 713 718.
41. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 24 : 7707 7717.
42. Stein TD, Johnson JA (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22 : 7380 7388.
43. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y (1994) High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 145 : 452 460.
44. Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M et al (2000) Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 157 : 331 339.
45. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92 : 4299 4303.
46. Togashi S, Lim SK, Kawano H, Ito S, Ishihara T, Okada Y et al (1997) Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 77 : 525 531.
47. Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T et al (2001) Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J Pathol 194 : 500 506.
48. Tomidokoro Y, Ishiguro K, Harigaya Y, Matsubara E, Ikeda M, Park JM et al (2001) Abeta amyloidosis induces the initial stage of tau accumulation in APP (SW) mice. Neurosci Lett 299 : 169 172.
49. Wang DS, Dickson DW, Malter JS (2006) beta-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006 : 58406.
50. Wei L, Kawano H, Fu X, Cui D, Ito S, Yamamura K et al (2004) Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo. Amyloid 11 : 113 120.
51. Weller RO, Cohen NR, Nicoll JA (2004) Cerebrovascular disease and the pathophysiology of Alzheimer's disease. Implications for therapy. Panminerva Med 46 : 239 251.
52. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH et al (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22 : 1858 1867.
53. Wu ZL, Ciallella JR, Flood DG, O'Kane TM, Bozyczko-Coyne D, Savage MJ (2006) Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging 27 : 377 386.
54. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS et al (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280 : 5892 5901.
55. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89 : 807 811.